CSIMarket
 
Biocardia Inc  (BCDA)
Other Ticker:  
 
 
Price: $0.4200 $0.02 3.704%
Day's High: $0.42 Week Perf: 5 %
Day's Low: $ 0.41 30 Day Perf: -8.7 %
Volume (M): 252 52 Wk High: $ 2.92
Volume (M$): $ 106 52 Wk Avg: $1.07
Open: $0.41 52 Wk Low: $0.36



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Biocardia Inc
Biocardia Inc. is a medical technology company that specializes in the development and commercialization of innovative therapies for cardiovascular diseases. The company focuses on regenerative medicine to address the limitations of current treatment options for heart failure, myocardial infarction, and chronic ischemic coronary artery disease.

Biocardia Inc. has developed a proprietary biotherapeutic delivery system called Helix Biotherapeutic Delivery System. It enables targeted delivery of biotherapeutic agents to the heart muscle, promoting tissue regeneration and healing. The system uses a catheter-based delivery method to precisely deliver the biotherapeutic agents to the desired location in the heart.

The company's main product, CardiAMP Cell Therapy, utilizes the Helix system to deliver a patient's own bone marrow-derived cells to the damaged heart tissue. This therapy aims to improve heart function, reduce symptoms, and enhance the quality of life for patients with heart failure. Biocardia Inc. is engaged in clinical trials to further evaluate the safety and efficacy of this therapy.

In addition to CardiAMP Cell Therapy, Biocardia Inc. is also developing other novel therapeutics and solutions for cardiovascular diseases. The company's mission is to provide innovative and effective treatments to improve patient outcomes in the field of cardiology.


   Company Address: 320 Soquel Way Sunnyvale 94085 CA
   Company Phone Number: 226-0120   Stock Exchange / Ticker: NASDAQ BCDA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Biocardia Inc

Breaking down Biocardia Inc's Fourth Quarter 2023 Effort: Revenue Tumbles



Biocardia Inc, a leading biotechnology company, has witnessed a significant decline in its share price over the past month, while its strategic partner, StemCardia, experienced a modest increase. These developments, combined with the company's recent financial results, have raised questions about the future outlook for Biocardia Inc.
1. Heart Failure as a Global Health Concern:
Heart failure remains a major global health concern, causing high morbidity and mortality rates. Biocardia Inc's aim to revolutionize biotherapeutic delivery in heart failure treatment shows its commitment to addressing this critical challenge. The company's strategic partnership with StemCardia highlights its intent to offer innovative approaches to combat this complex condition.

Partnership

Advancing Cardiac Biotechnology: BioCardia and StemCardia Forge a Promising Partnership for Targeting Heart Failure

Published Wed, Mar 13 2024 11:00 AM UTC

I. Heart failure remains a major global health concern, associated with significant morbidity and mortality rates. The limited treatment options available for this condition have prompted BioCardia, a leading biotechnology company, and StemCardia, a pioneering stem cell therapeutics firm, to join forces in a strategic partnership aimed at revolutionizing biotherapeutic deliv...

Product Service News

CMS Approves Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study, Augmenting Treatment Options

Published Tue, Mar 12 2024 11:00 AM UTC

In a groundbreaking move for the field of regenerative medicine, BioCardia, a leader in cardiovascular therapies, has received approval from the Centers for Medicare & Medicaid Services (CMS) to provide reimbursement coverage for the confirmatory Phase III clinical trial of their innovative CardiAMP heart failure study. This milestone represents a significant step forward in...

Product Service News

BioCardia Reports Promising Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, Targeting Elevated NTproBNP Biomarker

Published Mon, Mar 4 2024 1:00 PM UTC

SUNNYVALE, Calif., March 04, 2024 - BioCardia, Inc. (Nasdaq: BCDA), a leading biotechnology company specializing in late-stage cell therapy interventions for cardiovascular disorders, has announced positive interim results from its Phase III randomized controlled trial of CardiAMP autologous cell therapy. The trial involved 110 patients with advanced chronic heart failure ...

Clinical Study

BioCardia's CardiAMP Heart Failure II Phase 3 Pivotal Study Receives FDA Approval, a Major Step Towards Evolving Cardiovascular Intervention

Published Thu, Feb 8 2024 12:00 PM UTC

BioCardia, a leading biotechnology company dedicated to advancing cell therapy interventions for cardiovascular disorders, recently announced the activation of its highly anticipated CardiAMP Heart Failure II Phase 3 Pivotal Study. This groundbreaking study, recently approved by the Food and Drug Administration (FDA), marks a significant advancement in the field of cardiovas...






 

Biocardia Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biocardia Inc does not provide revenue guidance.

Earnings Outlook
Biocardia Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com